ALK and neoplasm: Similarly, YAP/TAZ are known to drive tumor proliferation and resistance in response to a variety of targeted therapies, including EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), MEK (mitogen-activated protein kinase kinase) and CDK4/6 (cyclin-dependent kinase 4/6) inhibitors19–26.